• Explore /
  • Poster
  • / Capmatinib efficacy in patients with NSCLC identified as <em>MET</em>ex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study.

Capmatinib efficacy in patients with NSCLC identified as METex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study.

Abstract Poster

Authors

null

Rebecca Suk Heist

Massachusetts General Cancer Center, Boston, MA

Rebecca Suk Heist , Edward B. Garon , Daniel Shao-Weng Tan , Harry J.M. Groen , Takashi Seto , Egbert F. Smit , Mike R. Zou , Yiqun Yang , Ying Li , Andrea Chassot-Agostinho , Juergen Wolf

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02414139

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9111)

DOI

10.1200/JCO.2021.39.15_suppl.9111

Abstract #

9111

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2021 ASCO Annual Meeting

Capmatinib in <em>MET</em> exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

First Author: Juergen Wolf

First Author: Harry J.M. Groen

First Author: Michael J. Overman

First Author: Xiuning Le